Please assess the completion status of the following clinical trial:

Trial Title: Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological SCC of the skin expressing (IHC) moderately or highly the EGFR (++ and +++, on a semi-quantitative scale).~* Locally advanced or metastatic SCC of the skin not suitable for local surgery with documented progression.~* Presence of at least one measurable target lesion by RECIST criteria.~* At least one lesion accessible to biopsies.~* ECOG Performance status \< 2.~* Life expectancy \> 3 months.~* Age \> 18 years.~* Normal hematological (Neutrophils \> 1.5x109 cells/l, platelets \> 100x109 cells/l), hepatic (bilirubin \< 1.5 times the upper limit of the normal range (ULN); alkaline phosphatase and transaminases \< 5 x UNL in case of hepatic metastases or \< 2.5 x UNL in absence of hepatic metastases) and renal (serum creatinine \< 150 micromol/L) functions.~* Written informed consent.~* In case of second tumor,excepted carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma, the possibility for including a patient may be discussed with the principal investigator.~Exclusion Criteria:~* Prior chemotherapy~* Prior radiotherapy \< 1 month.~* Prior therapy with agent targeting EGFR~* Unstable systemic diseases or active uncontrolled infections.~* Patients (male and female) not using effective contraception if of reproductive potential.~* Females pregnant or lactating. Women of child bearing potential must have a negative serum or urine pregnancy test prior to start each cycle of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cetuximab (Type: EXPERIMENTAL): cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).